Therapeutic strategies for leukodystrophy affected patients - LeukoTreat Videos

Intranet Print the page
Therapeutic strategies for leukodystrophy affected patients - LEUKOTREAT (Home)
Flux RSS des actualités News

04/12/2013

Documents to download

All documents prepared by the Ethics Research Group during LeukoTreat ...
See all news
Newsletter

Please enter your e-mail address

Last update : 09/02/2015

Videos

Hereafter are presented in more details each of the research axes of LeukoTreat.

 

Pr. Odile Boespflug-Tanguy - Project Coordinator

In this interview, Project Coordinator Pr. Boespflug-Tanguy from Robert-Debré Hospital (France), describes LeukoTreat and its objectives.

 

 

Dr. Enrico Bertini

In this interview, Dr. Bertini (Ospedale Bambino Gesu, Italy) describes the aim of the first research axis of the project, related to the collection of information on the epidemiology, the natural history, the genotype / phenotype correlation of LDs.

 

 

Dr. Hauke Werner
Dr. Werner (Max-Planck-Institut für Experimentelle Medizin, Germany), in charge of the third research axis of the project - Pharmacological strategies to treat leukodystrophies - here presents its objectives.

 

 

Pr. Patrick Aubourg
In this interview, Pr. Aubourg (Saint-Vincent de Paul Hospital, France), responsible for the fourth research axis of the project – Innovative gene and cell therapies for leukodystrophies – explains the objectives to be achieved.

 

Dr. Grégoire Moutel
Dr. Moutel (Paris-Descartes University, France) here describes the aim of the fifth research axis of the project, related to the ethical impacts of therapeutic challenges in leukodystrophies.